Note 14 Subsequent Events
On December 2, 2019, the Company received a redemption notice from the holder of the Companys June 2018 Convertible Note requesting a redemption of
$350,000, which, at the Companys election, was paid in cash rather than stock. Following this redemption, the outstanding balance on the June 2018 Convertible Note, including accrued interest, was approximately $2.6 million.
On December 6, 2019, the Company entered into subscription agreements with certain investors for the sale of 415 Series C convertible preferred shares at a
purchase price of $1,000 per share (December 6, 2019 offering). The investors in the December 6, 2019 offering also received warrants to purchase 1,037,500 shares of common stock with an exercise price of $0.30 per share and a five-year term.
The Company received net proceeds from the December 6, 2019 offering of approximately $0.38 million.
On December 9, 2019, the Company entered into
subscription agreements with certain investors for the sale of 2,568,330 shares of common stock at a purchase price of $0.30 per share in a registered direct offering (December 9 2019 Offering), pursuant to a registration statement on
Form S-3. The investors in the December 9 2019 Offering also received warrants to purchase 1,926,248 shares of common stock with an exercise price of $0.45 per share and a five-year term. The Company
received net proceeds from the December 9 Offering of approximately $0.75 million.
On December 13, 2019, the Company entered into
subscription agreements with certain investors for the sale of 2,433,333 shares of common stock at a purchase price of $0.30 per share in a registered direct offering (December 13 2019 Offering), pursuant to a registration statement on
Form S-3. The investors in the December 13 2019 Offering also received warrants to purchase 1,825,000 shares of common stock with an exercise price of $0.45 per share and a five-year term. The Company
received net proceeds from the December 13 Offering of approximately $0.73 million.
On December 16, 2019, the Company received a
redemption notice from the holder of the Companys January 2019 Convertible Note requesting a redemption of $350,000, which, at the Companys election, was paid in cash rather than stock. On December 27, December 30,
December 31, 2019 and on January 2, 2020, the Company received additional conversion notices from the holder of the January 2019 Convertible Note requesting conversions totaling $1.15 million. Pursuant to the January 2019 Convertible
Note, such conversions are at $0.50 per share. Accordingly, the Company issued 2.3 million shares in connection with such conversion notices. Following the aforementioned redemption and conversions, the outstanding balance on the January 2019
Convertible Note, including accrued interest, was approximately $4.2 million.
On December 17, 2019, the Company entered into a
Commercialization and License Agreement (the License Agreement) and a Supply Agreement (the Supply Agreement) with Vyera Pharmaceuticals, LLC, a Delaware limited liability company (Vyera). Pursuant to the License
Agreement, the Company granted Vyera an exclusive royalty-bearing license to commercialize pharmaceutical preparations containing leronlimab (PRO 140) for the treatment of HIV in humans in the United States. Pursuant to the terms of the License
Agreement, and subject to the conditions set forth therein, Vyera will bear the cost of, and be responsible for, among other things, the commercialization of leronlimab (PRO 140) in the United States. Pursuant to the Supply Agreement, the Company
has agreed to supply Vyera and Vyera has agreed to purchase from the Company, its requirements of leronlimab (PRO-140) for commercialization under the License Agreement. Under the terms of the Supply
Agreement, Vyera is obligated to make purchases of leronlimab (PRO 140) from the Company pursuant to Vyeras forecasted requirements, updated monthly, which will contain a binding period that will increase over the course of the first two years
following receipt of regulatory approval of leronlimab (PRO 140) for the treatment of humans with HIV.
On December 19, 2019, the Company issued
stock options covering 7,300,000 shares of its common stock to directors and officers. The stock option awards have a per share exercise price of $0.63. Stock options covering 6,050,000 shares vested immediately upon issuance and 1,250,000 shares
will vest upon filing of the BLA associated with HIV-Combination therapy. In addition, the president and chief executive officer received a warrant covering 2,000,000 shares with an exercise price of $0.63 per
share, which vests upon the Companys filing of the BLA.
On December 20, 2019, the Company entered into a private warrant exchange in which
certain accredited investors purchased unregistered common stock at a range of $0.22 to $0.25 per share as compared to the stated exercise price on their warrant, which ranged from $0.45 to $0.75 per share of common stock. The Company sold 3,350,000
shares of common stock, as well as 1,340,000 additional shares as an inducement to exercise their warrants, for a total of 4,690,000 shares of common stock, $0.001 par value. Aggregate gross proceeds from the private warrant exchange were
approximately $0.8 million.
As partial consideration for the License Agreement and the Supply Agreement, Vyeras parent company, Phoenixus AG
(Phoenixus), agreed to make a $4.0 million equity investment in the Company (the December 23 2019 Offering). On December 23, 2019, the Company entered into definitive subscription agreements relating to
Phoenixus investment. In addition to the $4.0 million of shares of common stock and warrants sold to Phoenixus, the December 23 2019 Offering also included $0.5 million of shares of common stock and related warrants sold to an entity
associated with David F. Welch, a member of the Companys board of directors, on terms identical to those applicable to Phoenixus. In the aggregate, the Company sold 14,754,098 shares of common stock and warrants to purchase up to an aggregate
of 7,377,049 shares of common stock. Each share of common stock was sold together with one-half of one warrant to purchase one share of common stock for a combined purchase price of $0.305 per share.
On December 24, 2019, the Company issued a total of 379,880 shares of registered common stock to two executives in connection with the stock portion of
their incentive compensation earned for the fiscal year ended May 31, 2018. The two executives simultaneously tendered back to the Company a total of 126,997 shares of the registered common stock to cover the income tax withholding
requirements.
On December 31, 2019, the holder of a 2019 Short-term Convertible Note in the aggregate principal amount of $549,912, including
accrued but unpaid interest, tendered a notice of conversion at the stated conversion rate of $0.50 per share. The Company issued 1,099,823 shares of Common Stock in satisfaction of the conversion notice.
25